<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064428</url>
  </required_header>
  <id_info>
    <org_study_id>103413</org_study_id>
    <nct_id>NCT00064428</nct_id>
    <nct_alias>NCT01352156</nct_alias>
  </id_info>
  <brief_title>OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction</brief_title>
  <official_title>An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blindcontrolled, parallel group, multi-center, multinational
      study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction)
      randomized within 24 hours of the onset of symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, controlled, parallel group, multi-center, multinational
      study of fondaparinux vs. control in patients with STEMI randomized within 24 hours of the
      onset of symptoms. Patients with confirmed STEMI were assigned into one of the following
      strata, based on local preference:

      Stratum 1: No indication for UFH; it is generally accepted that patients receiving
      streptokinase or those not receiving a thrombolytic agent were assigned to this stratum.

      Stratum 2: Indication for UFH; it is generally accepted that patients receiving a
      fibrin-specific agent (such as alteplase, reteplase or tenecteplase) or those undergoing
      primary PCI were assigned to this stratum.

      Patients who were ineligible for fibrinolysis (e.g. because of late presentation or absolute
      contra-indication for reperfusion therapy) may fall into either stratum 1 or stratum 2 at
      investigator's discretion. Following allocation to one of the strata, patients were
      randomized to fondaparinux or control treatment. Control treatment was dependent on whether
      the patient was assigned to stratum 1 or stratum 2:

      Stratum 1: fondaparinux sc* versus fondaparinux-placebo sc for 8 days or until hospital
      discharge, whichever was earlier.

      Stratum 2: fondaparinux sc* for 8 days or until hospital discharge, whichever was earlier and
      UFH-placebo for 24 to 48 hrs (or single bolus injection immediately prior to procedure in
      case of primary PCI) versus UFH for 24 to 48 hrs (or single bolus injection immediately prior
      to procedure in case of primary PCI) and fondaparinux-placebo for 8 days or until hospital
      discharge, whichever was earlier.

      (*First dose intravenous bolus) Patients were followed up for 6 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or recurrent myocardial infarction</measure>
    <time_frame>up to day 30</time_frame>
    <description>the first occurrence of any component of death (all-cause mortality) or recurrent myocardial infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe hemorrhage</measure>
    <time_frame>up to Day 9</time_frame>
    <description>Severe hemorrhage (modified TIMI criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death or recurrent myocardial infarction</measure>
    <time_frame>up to Day 9, 90 and 180</time_frame>
    <description>The first occurrence of any component of the composite of death (all-cause mortality) or recurrent myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, recurrent myocardial infarction or refractory ischemia</measure>
    <time_frame>up to Day 9, 30, 90 and 180</time_frame>
    <description>The first occurrence of any component of the composite of death (all-cause mortality), recurrent myocardial infarction or refractory ischemia</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12092</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Fondaparinux - UFH not indicated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - UFH not indicated</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondaparinux - UFH indicated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - unfractionated heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fondaparinux - UFH not indicated</intervention_name>
    <description>2.5mg od, sc (1st dose IV) x 8 days or discharge</description>
    <arm_group_label>Fondaparinux - UFH not indicated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control - UFH not indicated</intervention_name>
    <description>Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge</description>
    <arm_group_label>Control - UFH not indicated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux - UFH indicated</intervention_name>
    <description>2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion</description>
    <arm_group_label>Fondaparinux - UFH indicated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control - UFH</intervention_name>
    <description>UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge</description>
    <arm_group_label>Control - unfractionated heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who presented or were admitted to hospital with:

               1. Signs and symptoms of AMI

               2. Were able to randomize within 12 hours of symptom onset; and-

               3. Had definite ECG changes indicating STEMI: persistent ST-elevation (≥0.2mV in two
                  contiguous precordial leads, or ≥0.1mV in at least two limb leads), or new left
                  bundle branch block, or ECG changes indicating true posterior MI.

          -  Written informed consent

          -  Able to be randomized within 24 hours of symptom onset

        Exclusion Criteria:

          -  Age &lt;21 years.

          -  Was currently receiving an oral anticoagulant agent with an INR &gt;1.8.

          -  Had any contraindication to anticoagulation therapy such as high risk of bleeding or
             active bleeding.

          -  Had hemorrhagic stroke within the last 12 months.

          -  Had an indication for anticoagulation other than ACS.

          -  Pregnant women or women of child-bearing potential who were not using an effective
             method of contraception.

          -  Had a co-morbid condition with a life-expectancy &lt;6 months.

          -  Previous enrollment in one of the fondaparinux ACS trials.

          -  Participation in another pharmacotherapeutic study within the prior 30 days or was
             currently receiving an experimental pharmacological agent.

          -  Had a known allergy to heparin or fondaparinux.

          -  Had severe renal insufficiency (i.e. serum creatinine ≥3mg/dL or ≥265μmol/L).

          -  Had &gt;5000IU UFH administered prior to randomization.

          -  Had LMWH administered prior to randomization.

          -  Subject had pre-randomization revascularization (PCI) for the index event.

          -  Subject had pre-randomization rescue PCI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <results_reference>
    <citation>Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006 Apr 5;295(13):1519-30. Epub 2006 Mar 14.</citation>
    <PMID>16537725</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>October 16, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2003</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ST-segment elevation myocardial infarction</keyword>
  <keyword>fondaparinux</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>103413</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103413</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103413</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103413</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103413</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103413</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103413</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

